Early Real-World Description of Baseline Demographics and Clinical Characteristics of Patients with Plaque Psoriasis on Tapinarof Cream 1%

Main Article Content

Janine Fournier
Aseel Bin Sawad
Erin Zwick
Mariola Vazquez
Doral Fredericks
Anna Tallman
Krithika Rajagopalan


plaque psoriasis, tapinarof cream 1% once daily, real-world evidence, RWE, treatment, clinical practice, USA claims database study, All-Payor Claims Database


1. Dermavant Sciences. VTAMA (tapinarof) cream, 1%: US prescribing information. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215272s000lbl.pdf. Accessed September 2023.

2. Lebwohl MG, et al. N Engl J Med. 2021;385:2219–2229.

3. Strober B, et al. J Am Acad Dermatol. 2022;87:800–806.

4. Wu JJ, et al. J Comp Eff Res. 2020;9:767–779.

5. Feldman SR, et al. J Comp Eff Res. 2019;8:45–54.

6. Armstrong AW, et al. Dermatol Ther. 2017;7:97–109. 7. Chastek B, et al. J Dermatol Treat. 2013;24:25–33.

Most read articles by the same author(s)

1 2 > >>